Literature DB >> 24126039

Hypertensive posterior reversible encephalopathy syndrome causing posterior fossa edema and hydrocephalus.

Andrew J Grossbach1, Taylor J Abel2, Brendan Hodis2, Shafik N Wassef2, Jeremy D W Greenlee2.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a well characterized entity resulting from the inability of cerebral autoregulation to adequately protect the brain from uncontrolled hypertension. It primarily affects the occipital lobes, but can also involve the structures in the posterior fossa including the brainstem and cerebellum. Treatment usually consists of strict blood pressure control, but more aggressive management may be indicated with acutely worsening neurological status. We present a patient with hypertensive encephalopathy that resulted in hydrocephalus and brainstem compression necessitating surgical decompression requiring ventriculostomy and suboccipital craniectomy. In rare cases, PRES can present with severe brainstem compression requiring emergent posterior fossa decompression. When brainstem signs are present on exam, emergent posterior fossa decompression may be safer than ventriculostomy alone.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cerebellar edema; Hypertensive encephalopathy; Suboccipital craniectomy

Mesh:

Year:  2013        PMID: 24126039     DOI: 10.1016/j.jocn.2013.07.005

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  10 in total

1.  Posterior reversible encephalopathy syndrome coexists with acute cerebral infarction: challenges of blood pressure management.

Authors:  Luji Liu; Lihong Zhang
Journal:  Quant Imaging Med Surg       Date:  2020-12

Review 2.  Posterior reversible encephalopathy syndrome during the peripartum period: report of four cases and review of the literature.

Authors:  Hasan Buyukaslan; Ugur Lok; Umut Gulacti; Ozgur Sogut; Halil Kaya; Tahir Gokdemir; Oner Yalin
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Malignant systemic hypertension, encephalopathy and bradycardia following splenectomy for hereditary spherocytosis.

Authors:  Abhimanyu Varshney; Shilpa Sharma; Santosh Dey; Devendra K Gupta
Journal:  BMJ Case Rep       Date:  2015-05-24

4.  Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: a case report and literature update.

Authors:  Efterpi Pavlidou; Evangelos Pavlou; Athanasia Anastasiou; Zoi Pana; Vasiliki Tsotoulidou; Maria Kinali; Emmanuel Hatzipantelis
Journal:  Quant Imaging Med Surg       Date:  2016-10

5.  Hemodynamic changes of anesthesia, pneumoperitoneum, and head-down tilt during laparoscopic surgery in elderly patients.

Authors:  Dongyuan Jin; Hui Yu; Hai Li; Nannan Zhao; Ying Zhang; Junfeng Li; Jian Cui; Danian Tang; Yue Li; Yichao Teng; Ping Zeng
Journal:  Ann Transl Med       Date:  2021-07

6.  Pearls & Oy-sters: The dangers of PRES: An atypical case with life-threatening presentation.

Authors:  Christina Catherine; Claire Yanta; Aisha R Saand; Madison Pilato; Sherry H-Y Chou
Journal:  Neurology       Date:  2019-01-15       Impact factor: 11.800

7.  Acute Kidney Injury, Recurrent Seizures, and Thrombocytopenia in a Young Patient with Lupus Nephritis: A Diagnostic Dilemma.

Authors:  Hector Alvarado Verduzco; Anjali Acharya
Journal:  Case Rep Nephrol       Date:  2016-12-04

8.  An Unusual Case of Posterior Reversible Encephalopathy Syndrome.

Authors:  Robert P Zemple; Tomer Pelleg; Moises R Cossio
Journal:  Clin Pract Cases Emerg Med       Date:  2017-07-14

9.  Posterior Reversible Encephalopathy Syndrome Presenting as Stroke Mimic.

Authors:  Daniel Frick; Martin Huecker; Hugh Shoff
Journal:  Clin Pract Cases Emerg Med       Date:  2017-05-09

10.  Blood-Brain Barrier Disruption as a Potential Target for Therapy in Posterior Reversible Encephalopathy Syndrome: Evidence From Multimodal MRI in Rats.

Authors:  Quanlai Wang; Bin Huang; Guiquan Shen; Yu Zeng; Zheng Chen; Chunqiang Lu; Alexander Lerner; Bo Gao
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.